Bengt Westermark and our current understanding of tumor pathogenesis by Weinberg, Robert A.
Upsala Journal of Medical Sciences. 2012; 117: 81–82
FOREWORD
Bengt Westermark and our current understanding of tumor
pathogenesis
The ﬁeld of cancer research has advanced so far
over the past four decades—the precise time-span
of Bengt Westermark’s career—that it would be
unrecognizable to those who last visited it in 1972.
At that time, we knew that cancer cells grew uncon-
trollably and that a number of carcinogens were likely
to be genotoxic mutagens, i.e. that among their other
functions they worked to induce cancer through their
ability to damage the genes within human tissues.
That represented the entirety of our insights into
the molecular and cellular mechanisms underlying
cancer formation.
As it turned out, many of the insights in this area
ﬂowed from an unanticipated area. In the 1970s,
enormous efforts were invested in trying to ﬁnd a
variety of viruses that served as the causal agents of
human cancer. These viruses—so the thinking went—
infected cells in human tissues, transformed them into
cancer cells, and thereby triggered the outgrowth of
tumors. The discovery of retrovirus reverse transcrip-
tase in 1970 helped to feed this frenzy, including, in
the United States, the 1971 launching of Richard
Nixon’s War on Cancer.
The ﬂurry of activity searching for the retroviral
agents causing human cancer ultimately failed, but it
left a rich repository of information on genes that were
associated with rapidly transforming retroviruses, and
it was these genes, stolen from the genomes of normal
cells, that ultimately opened up the ﬁeld of molecular
oncology, more precisely the research that revealed
the molecular origins of human cancer.
These genes—proto-oncogenes and oncogenes—
turned out to be central players in triggering the
outgrowth of human cancers. Mutant cellular
growth-promoting genes were found to be the central
drivers forcing cancer cells to proliferate inexorably.
Of special interest was the research that undertook to
place these genes and their protein products in the
context of normal cell physiology. The question
therefore became: How do normal cell growth-
promoting genes become subverted by the process
of tumor pathogenesis?
It is precisely this question that focused the atten-
tion of Bengt Westermark, beginning 35 years ago. In
a prescient paper, he revealed that platelets, which
play a central role in blood-clotting and wound repair,
release factors that stimulate the growth of normal
glial cells. This implicated these factors in driving the
proliferation of normal cells and, quite possibly, that
of neoplastic cells.
By the late 1970s his group had led the charge
to identify a discrete growth factor—platelet-
derived growth factor (PDGF)—as a central agent
in this stimulation and the presence of a distinct
receptor on the surface of normal cells—the PDGF
receptor—that enables a variety of normal cells to
respond to PDGF in their surroundings. This
work, driven forward by the powerful collaboration
between Bengt Westermark and Carl-Henrik Heldin,
provided the conceptual framework for understan-
ding how the subversion of such a cellular growth-
stimulating pathway could lead to the runaway
proliferation of cancer cells. At the same time, it
revealed why and how serum was such a critical
ingredient in the complex media in which cells
were cultured then and now.
By 1985, their work led to the realization that
cancer cells often secrete growth factors, notably
PDGF, which then function on the same cells that
released them, inducing these cells to proliferate. This
led to the further insight that certain oncogenes,
notably the sis oncogene of a simian sarcoma virus,
function in this autocrine manner to drive cell proli-
feration. (This simian sarcoma virus was another fruit
of the 1970s stampede to ﬁnd cancer-causing human
retroviruses). Stated differently, unlike normal cells,
which depend on growth factor stimulation by their
neighbors before they undertake proliferation, cancer
cells will often make their own growth-stimulatory
(mitogenic) factors with which they alter their
surrounding microenvironment and stimulate their
own proliferation.
This theme of growth factor-mediated stimulation
of neoplastic cell growth has threaded its way through
Bengt Westermark’s opus in the succeeding three
decades and helps to explain why Uppsala became
one of the world’s leading centers in this type of
research. To be sure, his research expanded to
encompass other types of growth-stimulating factors,
such as epidermal growth factor (EGF) and thyroid-
stimulating hormone, and thus further extended and
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Because of the central role of PDGF signaling, this
research forms the core of our current understanding
of how gliomas—commonly occurring brain can-
cers—acquire the ability to grow relentlessly, with
an invariably fatal outcome. The Westermark opus
also provides many indications—speciﬁc molecular
targets—of how one can develop novel therapeutic
agents against brain tumors.
In my own case, I followed this research closely
since the mid-1970s, because it was so important and
so critical to forming my own conceptualization of
how cancer begins. It is for this reason that I was
especially honored and ﬂattered to have been recog-
nized by colleagues in Uppsala as the recipient of an
honorary doctorate from an institution that has come
to represent one of the world’s leading centers in the
area of molecular cancer research!
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